Elucidating the Significance of Zonulin in the Pathogenesis of Chronic Inflammatory Disorders: Emphasis on Intestinal Barrier Function and Tight Junction Regulation.
This review paper examines the role of zonulin — a protein that regulates intestinal tight junctions (TJs) — in the pathogenesis of Chronic Inflammatory Disorders (CIDs). The authors explore how dysregulation of zonulin contributes to increased intestinal permeability ("leaky gut"), which may facilitate the translocation of harmful substances from the gut into the bloodstream, potentially driving or worsening conditions such as Inflammatory Bowel Disease (IBD), celiac disease, and Multiple Sclerosis (MS). The paper synthesizes preclinical and clinical research on larazotide acetate, a zonulin antagonist, highlighting its potential to improve gut barrier integrity and reduce inflammation in CID patients. The authors also discuss zonulin's promise as a biomarker for intestinal permeability. Key limitations acknowledged by the review include the need for further mechanistic clarification of zonulin antagonists and robust clinical trials to establish their efficacy and safety. As a narrative review, this paper does not generate new primary data, and its conclusions are dependent on the quality and consistency of the underlying studies it synthesizes. The authors call for continued research to inform personalized therapeutic strategies for CIDs.
Why this grade: This is a narrative review synthesizing existing preclinical and clinical literature; it generates no new primary data and its evidence grade reflects the aggregated, indirect nature of review-level evidence.
The intestinal barrier, a critical component of the body's defense system, plays a vital role in maintaining homeostasis by preventing the translocation of harmful substances from the gut lumen into the bloodstream. Disruptions in this barrier, often characterized by increased intestinal permeability, are increasingly recognized as contributors to the development and progression of various Chronic Inflammatory Disorders (CIDs). Zonulin, a key regulator of intestinal Tight Junctions (TJs), has emerged as a pivotal player in this process. Dysregulation of zonulin, leading to increased intestinal permeability, has been implicated in the pathogenesis of a wide range of CIDs, including Inflammatory Bowel Disease (IBD), celiac disease, and Multiple Sclerosis (MS). This review examines the intricate relationship between zonulin and intestinal permeability, emphasizing its role in regulating TJ integrity and its association with various CIDs. Recent research has demonstrated the therapeutic potential of targeting zonulin, specifically through the use of larazotide acetate, a zonulin antagonist. Preclinical and clinical studies have shown promising results in improving gut barrier integrity and reducing inflammation in patients with CIDs. These findings underscore the significance of zonulin as a potential biomarker for intestinal barrier function and a promising therapeutic target for managing CIDs. Further research is needed to elucidate the precise mechanisms of action of zonulin antagonists and evaluate their efficacy and safety in clinical trials. A deeper understanding of the complex interplay among zonulin, intestinal permeability, and CIDs is crucial, paving the way for novel therapeutic strategies and personalized approaches to patient care.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.